Posted by Michael Wonder on 13 Dec 2021
European Commission approves Pfizer's Cibinqo (abrocitinib) for the treatment of adults with moderate to severe atopic dermatitis
10 December 2021 - Cibinqo is a once daily oral treatment with proven efficacy demonstrated in a large scale clinical trial program.
Pfizer today announced that the European Commission has approved the 100 mg and 200 mg doses of Cibinqo (abrocitinib), an oral, once daily, Janus kinase 1 inhibitor, for the treatment of moderate to severe atopic dermatitis in adults who are candidates for systemic therapy.
Additionally, a 50 mg dose was approved to treat moderate to severe atopic dermatitis specifically in patients with moderate and severe renal impairment or certain patients receiving treatment with inhibitors of cytochrome P450 2C19.
